// STATE LEGISLATION TRACKER

Pennsylvania HB 2027: An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, providing for opioid stewardship

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Pennsylvania
Bill: HB 2027
Filed: 2019-11-14
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Pennsylvania HB2027 was an opioid stewardship bill, not a peptide access bill. Based on the title and available bill history, it focused on opioid manufacturer/distributor fees, reporting, and funding opioid response programs, with no apparent change to compounded peptides, off-label peptide prescribing, telehealth, naturopathic scope, NP scope, or 503A/503B compounding.

Key Points

No direct peptide access change is apparent from the bill title or available history.
The bill targets opiates, not compounded peptides or peptide clinics.
No apparent telehealth, NP, naturopathic, or off-label prescribing expansion.
No apparent FDA 503A or 503B compounding rule change for peptides.

What to Watch For

Note Opioid-related reporting language could matter only if a clinic also handles controlled substances.

Note The bill appears unrelated to peptide compounding, prescribing, or patient access.

Concern If reintroduced more broadly, controlled-substance reporting duties could add admin burden for mixed-service clinics.

Where the Bill Stands

The bill was referred to the House Human Services Committee on November 14, 2019, and did not pass before the 2019-2020 session ended.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws